Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 847

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 847
---
2 |     | $          | 72,598 |     | $           | (112,200 | ) |     | $             | (39,600 | ) |

See accompanying notes to unaudited condensed financial statements F-87

#### SEMNUR PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Three Months EndedMarch 31,20252024Operating activitiesNet loss$(665)$(1,506)Adjustments to reconcile net loss to net cash used for operating activities:Stock-based compensation92179Changes in operating assets and liabilities:Prepaid expenses2(1)Accrued expenses172(831)Net cash used for operating activities(399)(2,159)Financing activitiesProceeds from related party loans1,2302,164Payments of deferred offering costs(836)—Net cash provided by financing activities3942,164Net change in cash and cash equivalents(5)5Cash and cash equivalents at beginning of period1212Cash and cash equivalents at end of period$7$17See accompanying notes to unaudited condensed financial statementsF-88
<div align='center'>**SEMNUR PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)**</div>

**Note 1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) was formed in 2013 and became a wholly owned subsidiary of Scilex Holding Company (“Scilex”) in 2019. The Company is a late clinical stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. The Company is currently developing one product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which the Company has completed a pivotal Phase 3 study (“SP-102” or “SEMDEXA”). Since inception, the Company has devoted all of its efforts to the development of SP-102 and operates in one segment. The Company is a Delaware corporation and is headquartered in Palo Alto, California.

On August 30, 2024, the Company entered into an agreement and plan of merger (as it may be amended